13F Holdings
中文EN

OCGN Ocugen, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1372299 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.3%
TTM net income YoY-24.7%
TTM EPS YoY-11.2%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,483.9%
Net margin-1,605.2%
FCF margin-1,334.3%
EBITDA margin-1,430.1%

Returns

ROE-660.0%
ROA-118.1%
ROIC (approx.)-1,221.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets89.8%
Debt / equity5.03x
Current ratio1.86x
Interest coverage-12.62x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.41M$4.05M$6.04M$2.49M$0
R&D expense$39.75M$32.13M$39.57M$56.16M$35.11M
SG&A expense$27.58M$26.69M$31.99M$35.40M$22.92M
Operating income-$62.92M-$54.76M-$65.53M-$89.07M-$58.03M
Interest expense$5.19M$688,000——$79,000
Pretax income-$67.85M-$54.05M-$63.08M-$86.80M-$58.42M
Income tax$0$0$0$0-$52,000
Net income-$67.85M-$54.05M-$63.08M-$86.80M-$58.37M
EBITDA-$60.52M-$52.86M-$64.83M-$88.59M-$57.80M
EPS (basic)——-0.26-0.40-0.30
EPS (diluted)——-0.26-0.40-0.30
Weighted avg. shares (diluted)——244.33M214.60M195.01M
Balance sheet
Cash & equivalents$18.57M$58.82M$39.46M$77.56M$95.11M
Short-term investments$0—$0$13.37M$0
Current assets$24.34M$61.68M$42.97M$98.49M$102.65M
PP&E, net$14.39M$16.55M$17.29M$6.05M$1.16M
Total assets$43.52M$82.44M$64.55M$108.63M$105.76M
Current liabilities$23.04M$21.59M$17.09M$28.53M$7.00M
Short-term debt$1.25M$1.33M$0$0$0
Long-term debt$27.54M$27.34M$2.80M$2.29M$1.71M
Total debt$28.79M$28.67M$2.80M$2.29M$1.71M
Total liabilities$55.68M$52.81M$23.98M$34.65M$9.94M
Shareholders' equity-$12.17M$29.63M$40.56M$73.98M$91.20M
Net debt$10.22M-$30.15M-$36.66M-$75.27M-$93.40M
Shares outstanding312.38M291.37M256.57M221.60M199.38M
Cash flow statement
Operating cash flow-$56.96M-$42.14M-$62.05M-$60.08M-$47.94M
Capital expenditure$185,000$3.38M$10.48M$4.46M$939,000
Free cash flow-$57.15M-$45.53M-$72.53M-$64.54M-$48.88M
Investing cash flow-$311,000-$3.38M$3.08M-$16.97M-$1.82M
Financing cash flow$17.33M$64.86M$20.88M$59.48M$120.68M
Depreciation & amortization$2.40M$1.90M$700,000$480,000$229,000
Stock-based compensation$7.71M$7.43M$9.22M$10.54M$6.96M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.